> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period Determined for Bayer’s Kovaltry
- URL: https://www.fdaweb.com/regulatory-review-period-determined-for-bayers-kovaltry/
- Published: 2017-10-06T12:00:00.000Z
- Updated: 2026-09-14T22:54:47.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139804

*Federal Register* notice: FDA has determined that the regulatory review period for patent extension purposes for Bayer’s Kovaltry (antihemophilic factor (recombinant)) is 2,478 days — of this, 2,021 days occurred during the testing phase and 457 days occurred during the approval phase. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-10-05/pdf/2017-21421.pdf?ref=fdaweb.com).